The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to accelerate recovery after liver surgery by enhancing intestinal passage through the preoperative use of Movicol.

Hypothesis The use of Movicol® during one week prior to partial liver resection combined with the Enhanced Recovery After Surgery (ERAS®) programme accelerates functional recovery by promoting early return of gastro-intestinal function, defined as the passage of stools and early oral intake.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Maastricht University Medical Center
• Collaborator: Norgine

Criteria

Inclusion Criteria:

• Patients undergoing a partial liver resection

• Able to understand the nature of the study and what will be required of them

• Men and non-pregnant, non-lactating women between age 18-80

• BMI between 18-35

• Patients with ASA I-III

Exclusion Criteria:

• Inability to give written informed consent

• Patients requiring bile duct reconstruction

• Patients with ASA IV-V

• Superextended hepatectomy

• Underlying symptomatic liver disease such as cirrhosis

• Underlying gastro-intestinal disease such as motility disorders

• Need for procedures additive to partial liver resection